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ajor depressive disorder (MDD) is considered a
major public health issue related to considerable
morbidity and disability.1,2 In addition, about half
of patients with MDD will respond either partially or not
at all to first-line antidepressant monotherapy, despite an
adequate dosage and a sufficient duration of treatment.3
For these patients, there is a clear need to study next-step
antidepressant therapies, and reliable efficacy data are re-
quired in order to produce meaningful statistical analysis
and increase the likelihood of finding effective, clinically
applicable treatments.
We describe here a new instrument, the clinician-rated
Massachusetts General Hospital SAFER interview. The acro-
nym stands for interview’s attention to the following criteria:
State versus trait; Assessability; Face validity; Ecological valid-
ity; and Rule of three Ps (pervasive, persistent, and patholog-
ical). These criteria facilitate the assessment of important
supplemental factors that go well beyond conventional diag-
nostic criteria and symptom severity to identify patients who
would be valid for clinical trials. The use of SAFER might
increase the quality of clinical trials by separating placebo re-
sponders from active drug responders and by restricting the
sample to a more homogenously defined MDD population.
That is, SAFER can help to ensure that patients are enrolled
in studies that will allow assessment of the treatment modal-
ity’s efficacy by minimizing the risk that factors unrelated to
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d Review of PsychiatryTHE NEED FOR A NEW INSTRUMENT
Reliance on a categorical system of psychiatric nosology, such
as the currently employed rigorous classification system of
the Diagnostic and Statistical Manual of Mental Disorders
(DSM),4 may not be sufficient for contemporary antidepres-
sant drug development.5 First, the current DSM-5MDD cri-
teria allow for the inclusion of patients with heterogeneous
symptoms representing several depressive syndromes/subtypes.
Second, a large number of symptoms commonly reported by
depressed patients are not captured by the DSM-5 (e.g., soma-
tic symptoms, such as headache, abdominal pain, musculo-
skeletal pain in the lower back, joints, and neck).6,7 Third,
situational factors (e.g., comorbid conditions, concurrent
medications, or external circumstances) may contribute to
episodes that appear similar to MDD but that fluctuate
widely because of external psychosocial changes rather than
because of treatment or spontaneous remission/exacerbation
of the depressive illness. While DSM-5 now includes bereave-
ment under the MDD diagnostic umbrella, other situational
factors may be contributing to depressive symptoms to such
an extent that including such a patient in a clinical trial for
the treatment of depression may be inappropriate.*
Used in conjunction with established structured diagnos-
tic instruments and symptom severity scales, SAFER over-
comes many of these obstacles. It is not restricted to the
DSM criteria, and it allows for other symptoms observed
during the clinical interview, as well as situational factors,
to be considered in evaluating eligibility for clinical trials.
It also allows patients to be ruled out in cases where the
symptomatology may not be strictly secondary or specific
to MDD.
THE OPERATIONALIZATION OF SAFER CRITERIA
We have sought to use SAFER to refine the diagnosis of de-
pression by assessing the persistence, pervasiveness, and
pathological nature of the current depressive episode.5 The
SAFER interview aims to confirm the diagnosis and exclude* The reader should note that, although this manuscript was originally written
based on our experience with DSM-IV MDD, the issues of concern remain




Figure 1. The SAFER is used at three steps of the clinical interview for
a clinical trial. First, the SAFER (Figure 2) is used in addition to structured
or semi-structured clinical interviews (e.g., the Structured Clinical Interview
for DSM-IV [SCID] or Mini–International Neuropsychiatric Interview [MINI]).
Second, the rule of the three Ps (i.e., Pervasiveness, Persistence, and
Pathological, see Figure 2) is used for each depressive symptom revealed by
the clinical interview, with or without the use of standard instruments for
assessing depression severity (e.g., the Montgomery–Åsberg Depression
Rating Scale (MADRS) or Hamilton Rating Scale for Depression (HAM-D)).
Third, the SAFER criteria (Text Box 1) are ﬁlled out, and the patient is
included or excluded from the clinical trial.
M. Desseilles et al.any depression that appears to be a trait, not a state, and any
symptoms that are nonspecific or not readily assessable.5 The
overall concept is depicted in Figure 1.
The principles of the SAFER criteria and a description of
the 3Ps –persistence, pervasiveness, and pathology– are
presented in Figure 2.
Assessability means that the patient should be able to
answer the clinician’s questions—both from the depression
scale and the general interview—in a relatively clear and
unambiguous manner. Patients who, for example, pro-
vide many qualifiers to each answer, who provide data that
are contradictory or inconsistent, or who seem to haveFigure 2. The SAFER criteria. The Rule of the Three Ps (for Pervasiveness, Per
mood, fatigue, guilt, and sleep disturbances). The clinician asks about these cha
symptoms that may appear during the clinical interview.
2 www.harvardreviewofpsychiatry.orgdifficulty understanding the questions would not likely
yield useful data in a clinical trial, as it is difficult to de-
termine whether they are actually in a major depressive ep-
isode (MDE), how severe their symptoms are, and whether
those symptoms change over the course of the treatment
period.
Face validity refers to the patients’ symptoms clearly
mapping to those of DSM-5MDD—namely, daily depressed
mood, anhedonia, sleep disturbance, and so on.
Ecological validitymeans that the symptoms should pres-
ent the way that we know them to present in classic MDD.
For example, a patient with MDD is expected to be de-
pressedmost of the day nearly every day. A patient who is de-
pressed about half of all days, and who may have frequent
periods of several weeks of euthymia alternating with
periods of depression, does not seem like the usual MDD pa-
tient, and also would not be a good candidate for a study, as
his symptoms would be too volatile to allow assessment of
the efficacy of a new treatment.
Operationalization of the SAFER involves the use of fo-
cused questions around the 3Ps: pervasiveness, persistence,
and pathology. Historically, we operationalized the SAFER
criteria by inquiring about the 3P’s for every symptom of
the depression scale used in the study—for example, the
Hamilton Depression scale. More recently, we have found
that focusing the SAFER questions on the DSM symptoms
of depression that the patient endorses, either individually
or in a global manner, is more efficient and less cumbersome
for the clinician and the patient. Each of the instrument’s
9 items are applied globally: does the overall presentationsistence and Pathological) is used for depressive symptoms (e.g., depressed
racteristics for EACH item on the basic depression questionnaire and for any
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Text Box 1
Operationalization of the SAFER Criteria
SAFER Criteria Inventory
(© Massachusetts General Hospital)
1. Persistent Symptoms:
□ Definitely (All of the patient’s symptoms are present
most of the day, nearly every day)
□ Possibly (Some, but not all, symptoms are present
most of the day, nearly every day)
□ Unlikely (Themajority of the symptoms are not pres-
ent most of the day, nearly every day)
2. Pervasive Symptoms:
□ Definitely (Symptoms impact all domains and/or
contexts)
□ Possibly (Symptoms impact many domains and/or
contexts, but not all)
□ Unlikely (Symptoms impact a minority of domains
and/or contexts)
3. Pathological Symptoms:
□ Definitely (Symptoms are disruptive and have af-
fected behavior or function, and are distinguishable
from the patient’s normal functioning)
□ Possibly (Symptoms are sometimes disruptive of be-
havior or function, or are not reliably distinguishable
from the patient’s normal functioning)
□ Unlikely (Symptoms are not disruptive and have not af-
fected the patient’s behavior or function, and are not
distinguishable from the patient’s normal functioning)
4. State (not Trait) Symptoms:
□ Definitely (Patient can remember a time when he or
she felt well.)
□ Possibly (Patient may remember a time when he or
she felt better, though the depression appears to be
an exacerbation of previous dysthymia or chronic
depression)
□ Unlikely (The patient is chronically dysthymic or de-
pressed with no identifiable reference point for a well
period.)
5. Acute Symptoms:
□ Definitely (Patient has symptoms of depression that be-
gan or worsened during the current episode)
□ Possibly (Symptoms of depression do not appear to
have begun with the current episode)
□ Unlikely (Patient does not have symptomsof depression)
6. Specificity of Symptoms:
NOTE: A situational depression may improve or worsen
in response to external circumstances. Thus, symptomatic
change (either improvement or worsening) may not be re-
liably attributed to drug treatment.
□ Definitely (Patient hasMDD does not have any other
condition as the primary cause of these symptoms)
□ Possibly (There is significant doubt as to whether
MDD is the primary diagnosis, because patient ap-
pears to have a symptomatic condition, e.g., PTSD
or GAD, that may be responsible for many or most
of the symptoms)
□ Unlikely (Patient’s symptoms are likely caused by
something other than MDD: another medical or
psychiatric diagnosis, concomitant medications, al-
cohol or drug abuse, external circumstances, or, the
depressive episode seems highly situational and the
patient may spontaneously improve with changed
circumstances)
7. Valid Symptoms (Ecological and Face Validity):
Using the responses obtained from the severity scale and
SAFER questions 1–6, ascertain whether:
a) Symptoms clearly map to the primary nosological en-
tity and occur with the frequency, intensity, duration,
course, and impact consistent with our knowledge
of DSM-diagnosed MDD in a real-world setting.
Symptoms do not map more closely to any other con-
ditionwhichmight be considered a primary diagnosis,
e.g. PTSD.
b) Symptoms are not exaggerated, they represent a
change from baseline, and they have had real impact
on behavior or level of function over at least the past
4 weeks.
c) Symptomatic change is likely to matter to the
patient’s quality of life.
d) If recurrent, the characteristics of the current epi-
sode are similar to previous episodes. (Ask the pa-





□ Definitely (Patient answers questions with reasonable
certainty, there is good internal consistency between
answers to items, and the patient rarely stumbles,
seems unsure, or contradicts himself/herself)
□ Unlikely (Patient stumbles on answers, answers in
non sequiturs or digresses a lot, doesn’t seem sure
of answers, and/or contradicts herself/himself in an-
swering questions)
The patient’s symptomsmust be able to be reliably and sen-
sitively measured with the employed rating instruments.
9. Valid Patient (meets ALL SAFER criteria for this clin-
ical trial):
□ Yes (SAFER questions 1–4 must be scored as “Def-
initely” or“Possibly,” andSAFERquestions5–8must
be scored as “Definitely”)
□ No (The above conditions for “Yes” are not met)
A response of “Unlikely” to any of questions 1–8 means
that the patient will be a SAFER fail.
SAFER Criteria
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SAFER is designed to focus on the entire period of depres-
sion, as described by the patient. However, if the depression
is long-standing or has had a fluctuating course, we instruct
clinicians to focus on the past month, to facilitate the data-
gathering process.
The operationalization of the SAFER criteria is depicted
in Text Box 1. A score of 1means that the answer to the ques-
tion posed in the item is “definitely,” meaning, for example,
that the symptoms have been present during the acute epi-
sode (item 5). A score of 2 means the answer is “possibly,”
meaning that the answer is less clear but is, overall, thought
to be affirmative; for example, a case of a depression that be-
gan shortly after a job loss might cast doubt on item 6 (spec-
ificity of symptoms) and would earn a score of 2. A score
of 3 means that the answer to the question of interest is
“unlikely”; for example, a patient who cannot give clear
answers to the clinician would get a rating of 3 on the item
8 (assessability).For items 1 to 8 in the text box (Operationalization of
the SAFER Criteria), the rater will select the score 1 (Defi-
nitely), 2 (Possibly) or 3 (Unlikely). Then, at item 9, the
rater will assess the overall validity of the patient as a study
candidate. This requires that the first four symptom criteria
(the 3Ps, and state vs. trait) should be scored Definitely or
Possibly (score 1 or 2), and items 5 (Acute Symptoms), 6
(Specificity of Symptoms), 7 (Valid Symptoms [Ecological
and Face Validity]), and 8 (Assessable Symptoms) have to
be scored Definitely (score 1). A yes on item 9 (Valid pa-
tient) would represent a SAFER “pass” if the patient has
sufficient and valid target symptoms of the primary noso-
logical entity, and for at least four weeks, to yield meaning-
ful, measurable scores in a clinical trial. A SAFER “fail”
will occur when the symptoms are not present (item 5 is
Possibly or Unlikely), are nonspecific to depression (item
6 is Possibly or Unlikely), have no ecological or face valid-
ity (item 7 is Possibly or Unlikely), or the patient is not as-
sessable (item 8 is Possibly or Unlikely)THE POTENTIAL ADVANTAGES OF SAFER
Nuanced Approach to Depression and Pathophysiological
Processes
SAFER is not limited to a symptom list; instead, it takes into
account a variety of symptoms in depressed patients that can
be psychological or somatic8 and that may be based on un-
derlying pathophysiological processes. This more nuanced
approach is important because,4since the publication of DSM-III in 1980, there
has been a steady decline in the teaching of care-
ful clinical evaluation that is targeted to the indi-
vidual person’s problems and social context and
that is enriched by a good general knowledge ofwww.harvardreviewofpsychiatry.orgpsychopathology. Students are taught to memorize
DSM rather than to learn complexities from the
great psychopathologists of the past.9(p108)Consideration of the complexity of a person’s symptom
constellation (i.e., a phenomenological approach) might be
reinstituted by the systematic use of SAFER in clinical trials.
SAFER inquires about possible causes of depression that are
not attributable to MDD per se—for example, depressive
symptoms secondary to medical illness (e.g., hypothyroid-
ism), concurrent medication side effects (e.g., from inter-
feron), and comorbid psychopathology (e.g., posttraumatic
stress disorder). By properly attributing symptoms, SAFER
could therefore provide a clearer diagnosis of the patient.
Potential for Reanalyzing Data from Large Studies
It might be worthwhile to reanalyze data from large studies
by applying post hoc SAFER criteria to dichotomize patients
as “SAFER passes” or “SAFER fails” and then reinterpret
the results. This approach may give additional insight into
the actual efficacy of antidepressant treatment in patients
who are more rigorously selected for depression—whose
symptoms might be more tractable with antidepressants.
Thus, by reanalyzing data from older studies that have avail-
able information about these factors, we could, for example,
remove patients who are “SAFER fails” and analyze only
patients who are “SAFER passes.” We might, as a result, ob-
tain different efficacy findings for the experimental therapy
of that particular study. This same approach could be applied
to individual chart reviews by clinicians in practice, particu-
larly in cases of complex patients who have not responded
well to treatment. The implementation of SAFER in clinical
settings may therefore enrich the psychiatric diagnostic pro-
cess, allowing for a more precise understanding of the
patient’s situation and assisting in the selection of effective
treatments.
Development of More Targeted Treatments
The use of SAFER might lead to the development of
treatments targeting specific symptoms and subpopulations
of patients, which may result in fewer trials of inappropriate
therapies and thus more rapid alleviation of depressive
symptoms. This approach may also encourage pharmaceuti-
cal companies to develop drugs for more narrowly defined
depressive syndromes and subtypes, as opposed to drugs
targeting the largest number of individuals. Narrower treat-
ment indications may pose a marketing/economic challenge,
but targeting specific treatment populations may increase
signal detection in two ways: by decreasing variability due
to diagnostic heterogeneity and by decreasing the time
needed to identify an appropriate treatment for a specific pa-
tient, thus saving precious time for the patient and clinician.
CASE ILLUSTRATIONS
Below are four case illustrations of patients that the SAFER
identifies as not appropriate for a clinical trial.Volume 21 • Number 5 • September/October 2013
SAFER Criteria
Ha– A subject became depressed one year ago. He attributes
his depression largely to many years of psychosocial
stressors or external factors and recognizes that a
change in life circumstances would do much to im-
prove his depression. In particular, he attributes his de-
pression to being laid off from his job. He believes that
a new job will alleviate his depression and that a drug
could not change anything because he has been through
a similar situation before, with depressive symptoms that
started when he was laid off five years ago and that im-
proved when he got a job. Such a patient would fail the
SAFER assessment due to lack of specificity arising from
external circumstances (the loss of his job) (Figure 2).
During the relatively short period of the clinical trial, it
would be hard to ascertain the origin of a symptom’s im-
provement (either the antidepressant or the new job).
– A subject has been depressed all her life and cannot
recall a time in her life when she felt happier for more
than a few hours, and even those occasions were
rare. This patient would fail the SAFER on the ground
of “state versus trait” symptoms, meaning that the
symptoms represent a chronic, long-standing trait char-
acteristic and are unlikely to change during a brief
pharmacological intervention. The situation would
potentially be different, though in cases of “double dep-
ression” (MDD superimposed on dysthymia), where an
exacerbation of preexisting symptoms may be measurable
(Figure 2).
– When describing her past psychiatric history, a subject
recalls being very depressed for a year. She intermit-
tently has had symptoms for one to two weeks at a
time every few months. Although she reported signifi-
cant symptoms in the two-week window evaluated in
the Structured Clinical Interview for DSM-IV (SCID),
she also reports a past history of suddenly feeling al-
most completely cured a few days after starting an
antidepressant. Closer examination of the overall
timeline raises the question of whether this case is ac-
tually one of MDD, because the overall course of the
illness and this rapid recovery is not consistent with
what is knownaboutMDD in the “realworld” (Figure 2).
This case would constitute a SAFER fail on the ground
that the symptoms lack ecological validity relating to
the overall course of the illness, severity of symptoms, or
presentation of symptoms. For example, symptoms that
are very intermittent may pass a SCID if captured in the
right window of two weeks, but they may fail a week
later at the SAFER interview if they have improved
or generally do not have a significant impact on the
patient’s condition. This case is one of a second-level
check to correct an initial interview with a SCID that
may have been a close pass.
– A subject has a hard time describing his mood and is
unable to answer interview questions in a clear and un-
ambiguous manner. His answers to questions aboutrvard Review of Psychiatryspecific symptoms are filled with qualifiers, digressions,
and irrelevant details, along with a general vagueness.
He has poor recall regarding the time course of his ill-
ness and symptoms, and is not able to describe how his
current state compares to his nondepressed baseline.
This case is a SAFER fail for a lack of assessability
(Figure 2).
LIMITATIONS
SAFER is not without limitations. First, this new instrument
requires systematic investigation of its face, construct, and
predictive validity or lack thereof. The instrument was
designed to be of use to research groups that carry out antide-
pressant clinical trials—in particular, by ensuring that
patients selected are more likely to have MDD as opposed
to “depression” that is purely secondary to situational
factors or to medication side effects, or that is simply not
consistent with the “real world” presentation of MDD. We
believe that SAFER could also be of use to clinicians in prac-
tice who are faced with the decision of whether to treat a pa-
tient with antidepressants, to recommend other interventions
(e.g., psychotherapy), or to simply observe the patient as he
or she negotiates a particular situation, such as searching
for a new job ormanaging grief. Patients who do not respond
to antidepressants in clinical trials, or who are placebo
responders, will often respond (or not) similarly in standard
clinical practice. Therefore, if clinicians use the SAFER in-
strument in their initial assessment of patients, it may allow
them to select treatment more effectively, which would im-
prove clinical care and presumably result in better outcomes.
Second, patients may retrospectively associate external
events with the onset of their symptomatology even when
objective evidence suggests no connection. Thus, in clinical
practice, the separation between “endogenous” and “reac-
tive” depression might be challenging or even impossible to
ascertain. While major life events (e.g., death of a loved
one) and the burden of minor stressors (e.g., daily hassles)
have been shown to predispose patients to MDD, SAFER
aims to tease apart depressive symptoms that might be
caused by an external event or context that may obscure
the potential clinical impact of the drug—or lack of it—
during the trial.
Third, by using the narrow SAFER inclusion criteria in a
clinical trial, we obtain a highly selected group of patients
with clearly defined episodic MDD leading to assessable
functional impairments. While this narrowing may contrib-
ute to improved signal detection in drug development, it
may limit generalizability of findings to a more narrow
population.
CONCLUSION
The SAFER criteria identify patients who, despite meeting
DSM criteria, would be poor candidates for drug trials.
By vetting patients for enrollment into clinical trials, we
hope to increase the likelihood of separation between novelwww.harvardreviewofpsychiatry.org 5
M. Desseilles et al.antidepressant treatments and placebo. To be eligible for
clinical trials, patients must have a clinical presentation
with both face and ecological validity that goes beyond
mere symptom identification. The assessment of diagnostic
validity could be made more accurate by the use of the
SAFER criteria. Finally, while we have used the SAFER pri-
marily for studies of MDD, the instrument could poten-
tially be adapted for use with other conditions, such as
bipolar disorder, anxiety disorders, or psychotic disorders.
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